SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-004989
Filing Date
2021-03-04
Accepted
2021-03-04 16:06:01
Documents
5
Period of Report
2021-03-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20210303_8k.htm 8-K 40597
2 EXHIBIT 3.1 ex_231642.htm EX-3.1 95295
3 EXHIBIT 10.1 ex_231643.htm EX-10.1 60286
4 EXHIBIT 10.2 ex_231644.htm EX-10.2 165148
5 EXHIBIT 99.1 ex_231645.htm EX-99.1 11409
  Complete submission text file 0001437749-21-004989.txt   374127
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 21714156
SIC: 2835 In Vitro & In Vivo Diagnostic Substances